Introduction: The Signal in the Noise
Quarterly earnings reports are dense, packed with data that can make it difficult to separate the crucial signals from the background noise. For a company as multifaceted as Gilead Sciences, understanding the true health and trajectory of the business requires looking beyond the headline figures. This analysis distills the company's Q3 2025 performance into the five most critical, data-driven takeaways for investors.
Beneath the headline numbers, the quarter reveals a strategic pivot in action: the predictable fade of a pandemic therapy is unmasking robust, durable growth in the company's core franchises. New products are gaining traction, and a significant strategic victory has extended the runway for its flagship drug. As CEO Daniel O’Day stated, the outlook is confident and focused on the future.
"With multiple potential product launches in 2026, the strongest clinical pipeline in Gilead’s history, and no major loss of exclusivity expected until 2036, we are well-positioned to drive positive impact for patients and continued growth of our business.”
Here are the five key numbers from Gilead's Q3 report that tell the real story.
--------------------------------------------------------------------------------
1. Headline Decline vs. Core Strength: The Veklury Effect is Fading
The first number to understand is the one that grabs the headlines, and the second is the one that truly matters. Total Product Sales for the third quarter were $7.3 billion, representing a decrease of 2% year-over-year.
However, this figure is skewed by the performance of Veklury, Gilead's COVID-19 therapy. When excluding Veklury, Total Product Sales were 7.1 billion**, an *increase* of **4% year-over-year**. Sales of Veklury itself decreased by **60% year-over-year** to **277 million due to lower rates of COVID-19-related hospitalizations. For investors, this marks a welcome clearing event, as the fading noise from Veklury allows the fundamental strength of Gilead's base business to become the primary driver of the narrative.
2. The HIV Powerhouse: Growth Despite a $900 Million Headwind
Gilead's HIV franchise remains a formidable growth engine, with Q3 sales increasing 4% year-over-year to 5.3 billion**. This performance is particularly impressive given that the company is managing an expected **~900 million headwind in fiscal year 2025 related to the Medicare Part D redesign.
The strength of the HIV portfolio was a key factor in the company raising its full-year 2025 HIV product sales growth guidance from ~3% to ~5%. The growth is broad-based across its leading and new products.
- Biktarvy: Sales increased 6% year-over-year to $3.7 billion. It has reached a record market share of approximately 52% in the U.S. treatment market.
- Descovy: Sales increased 20% year-over-year to $701 million, driven by strong demand in the HIV prevention (PrEP) market, which itself grew by approximately 14% year-over-year.
- Yeztugo (New Launch): The new, twice-yearly injectable for PrEP generated $39 million in its first full quarter. It has already achieved 75% payer access in the U.S. ahead of schedule and has been approved in Europe under the name Yeytuo.
This performance demonstrates a franchise firing on all cylinders—from the continued dominance of its flagship treatment Biktarvy to the surging demand in the PrEP market and the successful launch of a next-generation long-acting agent.
3. A Tale of Two Oncologies: Trodelvy Grows While Cell Therapy Falters
The Oncology franchise reported total sales of $788 million, down 3% year-over-year. This top-line figure, however, conceals a divergent performance within the portfolio, creating two distinct narratives for investors to follow.
The growth driver is Trodelvy, while the Cell Therapy unit is facing challenges:
- Trodelvy: Sales increased 7% year-over-year to $357 million. This growth was driven by higher demand, particularly in metastatic breast cancer, which more than offset the impact of the bladder cancer withdrawal in the U.S.
- Cell Therapy (Yescarta & Tecartus): Sales decreased 11% year-over-year to $432 million. The company attributes this to "continued competitive headwinds from in-and out-of-class therapies." As a result, Gilead now forecasts a full-year 2025 sales decline of approximately 10% for this segment.
This divergence places immense strategic importance on Trodelvy's pipeline. With the company awaiting regulatory decisions on Trodelvy's expansion into first-line metastatic TNBC in 2026, positive news here will be critical to offsetting the persistent competitive pressures in the Cell Therapy unit.
4. The 2036 Horizon: Biktarvy's Patent Cliff Just Got Further Away
One of the most significant updates of the quarter was not a financial figure but a strategic legal one. Gilead announced it had reached settlement agreements with several generic manufacturers regarding its blockbuster HIV drug, Biktarvy.
The direct impact of this is a crucial extension of the drug's market exclusivity. The earliest date a generic version of Biktarvy can be marketed in the U.S. has been moved from December 2033 to April 1, 2036. To put this in context, Biktarvy generated $3.7 billion in sales this quarter alone. Securing more than two additional years of market protection for its cornerstone product is arguably the most financially significant event of the quarter, locking in tens of billions of dollars in future revenue and providing a much longer runway to develop the next generation of therapies.
5. Emerging Growth Engine: Liver Disease Sales Jump 12%
Demonstrating successful diversification beyond its core HIV franchise, Gilead's Liver Disease portfolio sales increased 12% year-over-year to $819 million.
The primary driver of this growth is the impressive uptake of Livdelzi, a treatment for Primary Biliary Cholangitis (PBC). The drug's performance highlights its successful market launch and differentiation:
- Q3 sales reached $105 million.
- This represents a 35% increase compared to the previous quarter.
Livdelzi is now the #1 market leader for second-line PBC in the U.S. This provides powerful evidence for investors that Gilead's strategy to diversify beyond its core virology expertise is not just theoretical—the company can successfully execute commercial launches and capture market leadership in new therapeutic areas.
--------------------------------------------------------------------------------
Conclusion: Solid Core, Long Runway, Pipeline in Focus
Looking past the headline decline caused by fading Veklury sales, Gilead’s Q3 2025 results paint a picture of a healthy and growing core business. The HIV franchise continues to outperform even in the face of significant pricing headwinds, the patent runway for its cornerstone product Biktarvy has been extended by over two years, and new growth engines like Livdelzi are beginning to contribute meaningfully.
While the competitive challenges in the Cell Therapy market remain an area to watch, the company's overall financial and strategic position appears robust. With its core franchises secured for the long term and new growth drivers emerging, the key question for Gilead now is whether its extensive clinical pipeline can deliver the next blockbuster to fuel the company's growth into the next decade.
Comments
Post a Comment